1056 XTX301, a tumor activated, half-life extended IL-12 promoted potent anti-tumor immunity and activity across multiple syngeneic tumor models

Natalia V Malkova, Ekta Patel, Sallyann Vu, Damiano Fantini, Manoussa Fanny, Wilson Guzman, Stephanie Hsiao, Parker Johnson, Oleg Yerov, Kurt Jenkins, Hanumantha Rao Madala, Caitlin O’Toole, Jake Taylor, Magali Pederzoli-Ribeil, Ertan Eryilmaz, Benjamin Nicholson, Uli Bialucha, Jennifer O’Neil

Open source

DOI: 10.1136/jitc-2023-sitc2023.1056
Published: 2023-11
Container: Regular and Young Investigator Award Abstracts
Publisher: BMJ Publishing Group Ltd
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2023-sitc2023.1056,
  title = {1056 XTX301, a tumor activated, half-life extended IL-12 promoted potent anti-tumor immunity and activity across multiple syngeneic tumor models},
  author = {Natalia V Malkova and Ekta Patel and Sallyann Vu and Damiano Fantini and Manoussa Fanny and Wilson Guzman and Stephanie Hsiao and Parker Johnson and Oleg Yerov and Kurt Jenkins and Hanumantha Rao Madala and Caitlin O’Toole and Jake Taylor and Magali Pederzoli-Ribeil and Ertan Eryilmaz and Benjamin Nicholson and Uli Bialucha and Jennifer O’Neil},
  year = {2023},
  journal = {Regular and Young Investigator Award Abstracts},
  doi = {10.1136/jitc-2023-sitc2023.1056},
  url = {https://doi.org/10.1136/jitc-2023-sitc2023.1056}
}

RIS

TY  - JOUR
TI  - 1056 XTX301, a tumor activated, half-life extended IL-12 promoted potent anti-tumor immunity and activity across multiple syngeneic tumor models
AU  - Natalia V Malkova
AU  - Ekta Patel
AU  - Sallyann Vu
AU  - Damiano Fantini
AU  - Manoussa Fanny
AU  - Wilson Guzman
AU  - Stephanie Hsiao
AU  - Parker Johnson
AU  - Oleg Yerov
AU  - Kurt Jenkins
AU  - Hanumantha Rao Madala
AU  - Caitlin O’Toole
AU  - Jake Taylor
AU  - Magali Pederzoli-Ribeil
AU  - Ertan Eryilmaz
AU  - Benjamin Nicholson
AU  - Uli Bialucha
AU  - Jennifer O’Neil
PY  - 2023
JO  - Regular and Young Investigator Award Abstracts
DO  - 10.1136/jitc-2023-sitc2023.1056
UR  - https://doi.org/10.1136/jitc-2023-sitc2023.1056
ER  -

APA

Malkova, N. V., Patel, E., Vu, S., Fantini, D., Fanny, M., Guzman, W., Hsiao, S., Johnson, P., Yerov, O., Jenkins, K., Madala, H. R., O’Toole, C., Taylor, J., Pederzoli-Ribeil, M., Eryilmaz, E., Nicholson, B., Bialucha, U., & O’Neil, J. (2023). 1056 XTX301, a tumor activated, half-life extended IL-12 promoted potent anti-tumor immunity and activity across multiple syngeneic tumor models. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.1056

Source records

crossref · retrieved 2026-09-27T10:49:45.338Z